Melphalan flufenamide

Drug Profile

Melphalan flufenamide

Alternative Names: J-1; Mel-flufen

Latest Information Update: 04 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncopeptides
  • Class Amides; Amino acids; Antineoplastics; Fluorobenzenes
  • Mechanism of Action Alkylating agents; Caspase 3 stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Discontinued Bladder cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 31 Jan 2017 Phase-III clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Hungary (IV) (EudraCT2016-003517-95)
  • 27 Oct 2016 Phase-II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in Spain (IV) (EudraCT2016-000965-21)
  • 23 Mar 2015 Melphalan flufenamide receives Orphan Drug status for Multiple myeloma in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top